#1 Clinical Trials Search in Europe

Ovarian cancer recurrent – Trials in Disease

Go back

Ongoing Clinical Trials for Recurrent Ovarian Cancer

This article provides detailed information about 17 ongoing clinical trials studying new treatments for recurrent ovarian cancer. These trials are testing various medications and treatment combinations across multiple countries in Europe, offering potential treatment options for patients whose cancer has returned after initial therapy.

Clinical trial locations

Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

This trial focuses on patients with recurrent low-grade serous ovarian cancer. The study compares the combination of avutometinib and defactinib against standard treatment options selected by doctors.

Main inclusion criteria: Participants must be at least 18 years old and have a confirmed diagnosis of low-grade serous ovarian cancer that has recurred. They must have recovered from previous treatments and have at least one tumor that can be measured. The cancer must have returned or worsened after at least one round of platinum-based chemotherapy. Participants must also have a documented KRAS gene status and an ECOG performance status of 0 or 1, indicating they can carry out daily activities.

Main exclusion criteria: Patients without recurrent low-grade serous ovarian cancer, male patients, and vulnerable populations unable to provide consent are excluded from this trial.

Focus and goals: The study aims to evaluate whether the combination of avutometinib and defactinib is more effective than other available treatments in preventing disease progression. The primary goal is to assess progression-free survival, meaning how long patients live without their cancer worsening.

Investigational drugs: Avutometinib is a medication that blocks specific proteins involved in cancer cell growth. Defactinib targets enzymes that help cancer cells survive and spread. Both drugs are taken orally and are being tested for their ability to enhance treatment effectiveness.

Study of Azenosertib and Niraparib for Patients with Platinum-Resistant Ovarian Cancer

This study investigates platinum-resistant ovarian cancer using azenosertib, both alone and combined with niraparib, a drug already used in treating certain ovarian cancers.

Main inclusion criteria: Participants must have a confirmed diagnosis of recurrent high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer that is platinum-resistant. They must have tumors that can be measured and adequate blood and organ function. Participants need to provide a preserved tumor sample and be able to take medication by mouth.

Main exclusion criteria: Patients without platinum-resistant ovarian cancer, male patients, and those outside the specified age range cannot participate.

Focus and goals: The study is divided into two phases. The first phase determines safe dosage levels of azenosertib when used with niraparib. The second phase assesses how well these treatments reduce cancer. Researchers monitor for side effects and overall treatment impact.

Investigational drugs: Azenosertib is being studied for safety and effectiveness against cancer. Niraparib blocks a specific protein in cancer cells to help stop their growth. Both are administered orally as tablets.

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

This trial tests DS-3939a, delivered through intravenous infusion, for patients with advanced solid tumors including those affecting the ovary.

Main inclusion criteria: Participants must sign an informed consent form and have a left ventricular ejection fraction of at least 50%. They need measurable disease based on RECIST V1.1 criteria and an ECOG performance status of 0 or 1. Participants must have a confirmed diagnosis of locally advanced, metastatic, or unresectable cancer and have received specific previous treatments.

Main exclusion criteria: Patients with metastatic or advanced solid tumors who are not within the specified age range, part of vulnerable populations, or do not meet safety requirements cannot participate.

Focus and goals: The study evaluates the safety and tolerability of DS-3939a and measures its effectiveness at shrinking or controlling tumors. The first part focuses on safety, while the second part assesses effectiveness.

Investigational drugs: DS-3939a is a new medication designed to help treat advanced solid tumors by targeting specific pathways that cancer cells use to grow and spread.

Study of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer

This study combines pembrolizumab, an immunotherapy drug, with chemotherapy for patients with recurrent platinum-sensitive low-grade serous ovarian cancer.

Main inclusion criteria: Participants must be female, at least 18 years old, with confirmed low-grade serous ovarian, fallopian tube, or primary peritoneal cancer. They must have completed at least one platinum-based treatment and have platinum-sensitive disease. An ECOG performance status of 0 or 1 is required, along with adequate organ function and a tumor sample available for testing.

Main exclusion criteria: Patients without recurrent platinum-sensitive low-grade serous ovarian cancer, male patients, and vulnerable populations are excluded.

Focus and goals: The trial determines if pembrolizumab combined with chemotherapy can help patients live longer without disease progression. It also assesses treatment safety and quality of life impacts.

Investigational drugs: Pembrolizumab helps the immune system fight cancer cells by blocking a specific protein. It is given through intravenous infusion alongside chemotherapy.

Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This trial evaluates REGN5668, a bispecific antibody, combined with cemiplimab or REGN4018 for patients with certain gynecological cancers.

Main inclusion criteria: Participants must have a confirmed diagnosis of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. They must have received at least one platinum-based therapy and have adequate organ and bone marrow function. An ECOG performance status of 0 or 1 is required, along with a serum CA-125 level at least twice the normal limit.

Main exclusion criteria: Patients with medical conditions other than the specified cancers, male patients, and vulnerable populations unable to give informed consent are excluded.

Focus and goals: The study has two phases: determining the best dose of medications when used together and evaluating how well they work in a larger group. The aim is to enhance the immune response against cancer cells.

Investigational drugs: REGN5668 connects two different proteins to help activate immune cells. Cemiplimab blocks a protein that prevents immune cells from attacking cancer. REGN4018 directs immune cells to attack cancer cells.

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

This trial evaluates the zAvatar-test, which helps doctors decide the best treatment for patients with relapsed ovarian cancer and metastatic breast cancer.

Main inclusion criteria: Participants must be women aged 18 years or older with confirmed non-mucinous epithelial ovarian cancer. They must have measurable disease and an ECOG performance status of 0-2. Adequate bone marrow, liver, kidney, and heart functions are required. Participants must have a high amount of fluid in the abdomen or around the lungs requiring drainage.

Main exclusion criteria: Male patients and those not part of the female population are excluded.

Focus and goals: The study compares treatments chosen based on the zAvatar-test with those chosen by standard medical practice. The main goal is to improve progression-free survival.

Investigational drugs: The zAvatar-test is a predictive model that helps tailor treatment by analyzing specific cancer characteristics. Standard care involves usual treatments provided for managing the condition.

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

This trial compares olaparib, taken as a tablet, to standard chemotherapy treatments for patients with recurrent ovarian cancer after surgery.

Main inclusion criteria: Participants must be female, at least 18 years old, with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer that has recurred. They must have had only one previous platinum-based treatment and received first-line maintenance therapy with a PARP inhibitor for at least 6 months. Participants must have undergone surgery that removed all visible cancer and have a known BRCA1/2 status. An ECOG performance status of 0 to 1 is required, along with normal organ and bone marrow function.

Main exclusion criteria: Patients who have not undergone secondary cytoreductive surgery, male patients, and vulnerable populations are excluded.

Focus and goals: The study determines how effective olaparib is in maintaining health after cancer progression compared to standard chemotherapy. It also assesses overall survival, safety, and quality of life.

Investigational drugs: Olaparib is a PARP inhibitor that prevents cancer cells from repairing themselves, leading to their death. It is being tested to see if it works better than usual chemotherapy after surgery.

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

This trial focuses on patients with recurrent ovarian cancer who do not have mutations in the BRCA1 and BRCA2 genes, testing olaparib as a maintenance treatment.

Main inclusion criteria: Participants must be at least 18 years old, female, with relapsed high-grade ovarian, primary peritoneal, or fallopian tube cancer. They must not have BRCA1 or BRCA2 mutations and have an ECOG performance status of 0 to 2. Participants must have received at least two previous platinum-based chemotherapy treatments and be considered platinum sensitive. They must show a response to the last chemotherapy and have received at least four cycles of it. Adequate organ and bone marrow function is required.

Main exclusion criteria: Patients without recurrent ovarian cancer that is wild type for BRCA genes, male patients, and those outside the specified age range or part of vulnerable populations are excluded.

Focus and goals: The study explores how well olaparib works as a maintenance treatment after the cancer has responded to platinum-based chemotherapy. It monitors how long patients remain free from cancer progression and their overall survival.

Investigational drugs: Olaparib is used as a maintenance treatment to help keep the cancer from coming back by targeting cancer cells and preventing them from repairing themselves.

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

This study explores sacituzumab tirumotecan, a monoclonal antibody, used alone or with bevacizumab for platinum-sensitive recurrent ovarian cancer.

Main inclusion criteria: Participants must have a confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. They must have received at least 4 cycles of platinum-based chemotherapy in the first treatment and a total of 6 cycles in the second treatment. The cancer must be platinum-sensitive, and participants must provide a tumor tissue sample not treated with radiation. An ECOG performance status of 0 to 1 is required.

Main exclusion criteria: Patients without recurrent ovarian cancer, male patients, and vulnerable populations are excluded.

Focus and goals: The study evaluates how well sacituzumab tirumotecan with or without bevacizumab works in maintaining health after second-line platinum-based chemotherapy. It compares the effects against standard care, which may include observation or bevacizumab use.

Investigational drugs: Sacituzumab tirumotecan targets and delivers an anti-cancer drug directly to cancer cells. Bevacizumab blocks a protein that helps tumors grow new blood vessels, slowing cancer growth.

Study of Avutometinib and Defactinib for Patients with Recurrent Low-Grade Serous Ovarian Cancer

This trial tests avutometinib and defactinib, both taken orally, for patients with recurrent low-grade serous ovarian cancer.

Main inclusion criteria: Participants must be female, at least 18 years old, with confirmed recurrent low-grade serous ovarian cancer. The tumor must have a known KRAS mutational status and the cancer must have progressed after at least one previous treatment. Participants must have measurable disease and an ECOG performance status of 0 or 1. Adequate organ function is required, including good blood health, liver function, kidney function, and heart function.

Main exclusion criteria: Male patients, those without recurrent low-grade serous ovarian cancer, and vulnerable populations are excluded.

Focus and goals: The study aims to find the best way to use avutometinib and defactinib, either alone or together, to help patients. It monitors how well the cancer responds to treatment and any side effects that may occur.

Investigational drugs: Avutometinib blocks proteins involved in cell growth by targeting RAF and MEK pathways. Defactinib targets FAK, a protein that helps cancer cells survive and spread.

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

This study evaluates OSE2101, a cancer vaccine, alone or combined with pembrolizumab as maintenance therapy for platinum-sensitive recurrent ovarian cancer.

Main inclusion criteria: Participants must be at least 18 years old with confirmed non-mucinous epithelial ovarian cancer and HLA-A2 positive genetic marker. They must have good physical performance and be within 8 weeks from last chemotherapy treatment. Adequate organ function is required, and participants must have tumor tissue available for testing. Women of childbearing potential must use effective birth control and have a negative pregnancy test.

Main exclusion criteria: Patients with previous allergic reactions to cancer treatments, active autoimmune diseases, participation in another clinical trial within 30 days, male patients, those under 18 years, presence of active infections, significant heart problems, history of other cancers within the past 5 years, pregnancy or breastfeeding, known brain metastases, active hepatitis B or C, current treatment with experimental drugs, and history of organ transplantation are excluded.

Focus and goals: The study determines how effective OSE2101 and pembrolizumab are in preventing cancer progression after chemotherapy response. It compares two treatment approaches with standard supportive care.

Investigational drugs: OSE2101 is a cancer vaccine that stimulates the immune system to fight cancer cells. Pembrolizumab is an immunotherapy that helps the immune system detect and attack cancer cells by blocking the PD-1 pathway.

Summary

These 17 clinical trials represent a diverse range of investigational treatments for recurrent ovarian cancer. A significant number of trials are concentrated in countries such as France, Spain, Belgium, and Italy, reflecting strong research activity in these regions. Several trials focus on combination therapies, including immunotherapy agents like pembrolizumab and targeted therapies such as olaparib and avutometinib. Many studies specifically target platinum-resistant or platinum-sensitive disease, recognizing the different treatment needs for these patient populations. The trials also emphasize personalized medicine approaches, with some requiring specific genetic markers such as BRCA status, HLA-A2 phenotype, or folate receptor-alpha expression. Overall, these studies aim to improve treatment outcomes, extend progression-free survival, and enhance quality of life for patients with recurrent ovarian cancer.

Ongoing Clinical Trials on Ovarian cancer recurrent

  • Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Finland France Germany Ireland +4

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

More information about
Ovarian cancer recurrent:

Connected medications: